热毒宁联合磷酸奥司他韦治疗小儿甲型流感的临床效果及对临床症状、炎症因子水平的影响

Clinical Effect of Reduning Combined with Oseltamivir Phosphate in the Treatment of Children with Influenza A and Its Influence on Clinical Symptoms and Levels of Inflammatory Factors

目的:观察热毒宁联合磷酸奥司他韦治疗小儿甲型流感的临床效果及对临床症状、炎症因子水平的影响。方法:回顾性选取2023年1—6月吉安市第一人民医院收治的120例甲型流感患儿,按治疗方法不同分为对照组(n=60)、观察组(n=60)。对照组给予磷酸奥司他韦治疗,观察组给予热毒宁联合磷酸奥司他韦治疗,均连续治疗5 d。对比两组临床效果、临床症状、炎症因子及不良反应发生率。结果:观察组临床总有效率为96.67%,高于对照组的83.33%(P<0.05);观察组发热、流涕、咳嗽、鼻塞消失时间分别为(2.13±0.35)、(2.52±0.43)、(4.55±0.74)、(3.12±0.70)d,均短于对照组的(2.80±0.46)、(3.65±0.58)、(5.62±0.91)、(4.30±1.04)d(P<0.05);治疗后,两组白介素-6、C反应蛋白水平均较治疗前下降,且观察组[(26.70±4.58)ng/L、(9.74±2.89)mg/L]均低于对照组[(32.16±4.32)ng/L、(12.65±3.42)mg/L](P<0.05);两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论:热毒宁联合磷酸奥司他韦治疗小儿甲型流感,可有效抑制患儿机体的炎症反应,加快症状消退,疗效确切且安全性高。

Objective:To observe the clinical effect of Reduning combined with Oseltamivir Phosphate in the treatment of children with influenza A and its influence on clinical symptoms and levels of inflammatory factors.Method:A total of 120 children with influenza A admitted to the First People's Hospital of Ji’an City from January to June 2023 were retrospectively selected and divided into control group(n=60)and observation group(n=60)according to different treatment methods.The control group was treated with Oseltamivir Phosphate,and the observation group was treated with Reduning combined with Oseltamivir Phosphate,all children were treated continuously for 5 days.The clinical effect,clinical symptoms,inflammatory factors and incidence of adverse reactions were compared between the two groups.Result:The total effective rate of observation group was 96.67%,which was higher than 83.33%of control group(P<0.05).The disappearance time of fever,runny nose,cough and nasal obstruction in the observation group were(2.13±0.35),(2.52±0.43),(4.55±0.74)and(3.12±0.70)d,respectively,were shorter than(2.80±0.46),(3.65±0.58),(5.62±0.91),(4.30±1.04)d in the control group(P<0.05).After treatment,the levels of interleukin-6 and C reactive protein in both groups were decreased compared with those before treatment,and those in the observation group[(26.70±4.58)ng/L,(9.74±2.89)mg/L]were lower than those in the control group[(32.16±4.32)ng/L,(12.65±3.42)mg/L](P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Reduning combined with Oseltamivir Phosphate in the treatment of children with influenza A can effectively inhibit the inflammatory response of the children's body and accelerate the resolution of symptoms,with accurate efficacy and high safety.